IMRN Immuron Limited
1.090USD+0.93%Mkt Cap: 8.80M $P/E: —1d ago
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the Unit…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and | ||
Sector Update: Healthcare Stocks Decline Friday Afternoon Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H | ||
 IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today? Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S | ||
 Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement Immuron (NASDAQ:IMRN) has secured exclusive U. S. | ||